Palo Santo VC — 2022 Investments

1 investments dated 2022 · listed companies and verified rows first · show all

Gilgamesh Pharmaceuticalsgilgameshpharmaceutical.com in 𝕏Seed · Dec 2022 · $39Macquired by AbbVie · Aug 2025 · $1.2B

Gilgamesh Pharmaceutical develops novel chemical entities for psychiatric disorders using medicinal chemistry and AI-powered translational platforms to design rapid-acting therapies targeting neurobiological mechanisms rather than symptom management.

AI & Machine LearningBiotechDigital HealthHealthtechNew York City, US

Jonathan Sporn(Founder)inAndrew Kruegel(Founder)inDalibor Sames(Founder)inAndrew Kruegel, Ph.D.(Executive Officer)Thomas Kevin Murphy, Ph.D.(Executive Officer)JONATHAN SPORN(Founder)in

Co-investorsAera VC Alumni Ventures Awareness Venture Frontera Technology Ventures Frontier Path VC Gaingels +27 more

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.